Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06358534 Active, not recruiting - Clinical trials for Kidney Failure, Chronic

The Effect of Acceptance and Commitment Therapy in Patients With Chronic Renal Failure

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Psychological flexibility, life satisfaction and adaptation to the disease of individuals with chronic kidney disease were increased with psychoeducation based on acceptance and commitment therapy to be given to individuals with chronic kidney disease.

NCT ID: NCT05927415 Active, not recruiting - Renal Impairment Clinical Trials

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

A study to test how kidney problems influence the blood concentrations of efgartigimod

NCT ID: NCT05766644 Active, not recruiting - Clinical trials for Renal Insufficiency, Chronic

App-based Education Program for CKD

Start date: October 27, 2022
Phase: N/A
Study type: Interventional

A randomized control trial to test the effect of a mobile app-based educational program for Chronic Kidney Disease patients.

NCT ID: NCT05656040 Active, not recruiting - Clinical trials for Kidney Failure, Chronic

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Start date: February 8, 2023
Phase: Phase 1
Study type: Interventional

This is a three-part study of MK-2060 in participants with chronic and/or end-stage kidney disease. The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous dose of MK-2060 in stage 4 chronic kidney disease (CKD4) or stage 5 chronic kidney disease (CKD5) participants in Part 1, of multiple subcutaneous doses in CKD4 or CKD5 participants in Part 2, and of a single subcutaneous dose of MK-2060 in participants with end-stage kidney disease in Part 3. The primary hypothesis is that, in Part 1, the true geometric mean of the area under the concentration-time curve from 0 to infinity (AUC0-inf) after a single-dose of MK-2060 in adult CKD4 or CKD5 participants is at least 11300 nM*hr.

NCT ID: NCT05646615 Active, not recruiting - Quality of Life Clinical Trials

Experiences and Health-related Quality of Life of Informal Caregivers of Dialysis Patients

Start date: June 25, 2020
Phase:
Study type: Observational

The goal of this prospective, observational, multicentre cohort study is to assess the trajectory of the experiences (both positive and negative) and health-related quality of life (HRQOL) of informal caregivers of patients who start home dialysis, and compare these to experiences and HRQOL of informal caregivers of patients who start in-centre hemodialysis. The investigators hypothesise that informal caregivers of home dialysis patients experience more positive experiences, but also more negative experiences, and still have better HRQoL, compared with caregivers of in-centre HD patients. Participants will fill in five different validated questionnaires and questions on required support. Participants are asked to fill in the questionnaires after inclusion (i.e., start of dialysis), and at 6 and 12 months after start dialysis.

NCT ID: NCT05449496 Active, not recruiting - Obesity Clinical Trials

Dietary Intervention to Improve Kidney Transplant Outcomes

Start date: June 27, 2022
Phase: N/A
Study type: Interventional

Randomized controlled trial of a curriculum intervention teaching patients to eat a whole-food plant-based dietary pattern versus standard of care in kidney transplant recipients within the first few months of transplant

NCT ID: NCT05418816 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

SelfWrap-Assisted Arteriovenous Fistulas

SW-AVF
Start date: June 14, 2021
Phase: N/A
Study type: Interventional

This is a single-center, prospective, single-arm clinical study to evaluate the feasibility, safety, and performance of VenoStent's SelfWrap® Bioabsorbable Perivascular Wrap on arteriovenous fistulas (AVFs). All participants are chronic kidney disease (CKD) patients already receiving hemodialysis treatments that are referred for creation of a new arteriovenous fistula (AVF).

NCT ID: NCT05384899 Active, not recruiting - Covid19 Clinical Trials

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

Start date: June 15, 2021
Phase:
Study type: Observational

Since its inception, KPMP has developed sophisticated protocols for collection and analysis of human kidney tissue, and for collection of biofluids. Members of the consortium have wide-ranging expertise in conducting clinical studies, processing kidney tissue, advanced structural and molecular analysis and complex bioinformatics analysis, which will be used to leverage effectively as a group to better understand kidney disease. This joint protocol aims to synergize the COVID-19 study efforts of KPMP academic research centers, to collectively study COVID-19, including its renal presentation using kidney tissue and/or biofluids from patients suffering from COVID-19. This will increase the breadth and depth of data available to the public to expedite discoveries, identify therapeutics, and improve outcomes for patients with COVID-19. It will additionally bring the expertise of KPMP investigators to bear against this pandemic.

NCT ID: NCT05381961 Active, not recruiting - Hemodialysis Clinical Trials

Observational Study of BIS in Hemodialysis Patients

Start date: April 4, 2022
Phase:
Study type: Observational

This observational study will evaluate bioimpedance spectroscopy (BIS) measurements from patients undergoing hemodialysis.

NCT ID: NCT05112315 Active, not recruiting - Kidney Diseases Clinical Trials

Clinical Impact of the iBox as an Early Intervention tooL

Start date: February 18, 2022
Phase: N/A
Study type: Interventional

International, multicentre, randomized 1:1 controlled trial to prove the clinical and medico economic benefits of the medical device Predigraft, by showing that the use of Predigraft could improve patient's follow-up.